Gene: DENND11
Official Full Name: DENN domain containing 11provided by HGNC
Gene Summary: Predicted to enable guanyl-nucleotide exchange factor activity. Predicted to be active in cytoplasm. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO18313 | DENND11 Knockout cell line (HeLa) | Human | DENND11 | 1:3~1:6 | Negative | Online Inquiry |
KO18314 | DENND11 Knockout cell line (HCT 116) | Human | DENND11 | 1:2~1:4 | Negative | Online Inquiry |
KO18315 | DENND11 Knockout cell line (HEK293) | Human | DENND11 | 1:3~1:6 | Negative | Online Inquiry |
KO18316 | DENND11 Knockout cell line (A549) | Human | DENND11 | 1:3~1:4 | Negative | Online Inquiry |
DENND11 Gene Knockout Cell Lines are advanced cellular models specifically engineered to study the DENND11 gene's functional roles in various biological processes. These cell lines utilize CRISPR/Cas9 technology for precise and efficient gene disruption, allowing researchers to investigate gene function and its implications in cellular mechanisms, particularly in the context of cancer and neurological diseases.
The key functions of the DENND11 Gene Knockout Cell Lines involve the modulation of intracellular signaling pathways. By knocking out the DENND11 gene, which is implicated in membrane trafficking and the regulation of Rab GTPases, researchers can explore how these changes affect cellular processes such as proliferation, differentiation, and apoptosis. The manipulation of DENND11 offers insights into its potential role as a therapeutic target, contributing significantly to the understanding of pathophysiological mechanisms underlying various diseases.
The scientific importance of these cell lines lies in their ability to serve as a reliable platform for drug discovery and development, particularly in identifying novel therapeutic agents. In clinical settings, these models enable the testing of therapeutic strategies aimed at restoring normal gene function or compensating for the loss of DENND11 activity, thus providing a foundational tool for translational research.
What sets the DENND11 Gene Knockout Cell Lines apart from alternatives is their rigorously validated functionality and specificity in gene disruption. The reliability of CRISPR technology ensures the consistency of experimental results, which is critical for the reproducibility required in scientific research.
For researchers and clinicians, these cell lines represent an invaluable resource for dissecting the intricate roles of the DENND11 gene in health and disease. Their usability in high-throughput screening applications and in vivo studies enhances their appeal as a go-to model system for advancing biomedical research.
Our company specializes in the development of innovative biological products that empower scientists in their quest for groundbreaking discoveries. With a commitment to quality and excellence, we prioritize the needs of the research community, ensuring that our offerings, including the DENND11 Gene Knockout Cell Lines, are at the forefront of scientific advancement.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.